Rui Avelar Sells 27,904 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 27,904 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now directly owns 362,467 shares in the company, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Rui Avelar also recently made the following trade(s):

• On Monday, December 23rd, Rui Avelar sold 2,252 shares of Evolus stock. The stock was sold at an average price of $10.85, for a total value of $24,434.20.

Evolus Stock Performance

NASDAQ EOLS traded down $0.22 during trading hours on Thursday, hitting $13.25. The company had a trading volume of 663,321 shares, compared to its average volume of 593,757. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82. The company has a market cap of $842.53 million, a PE ratio of -14.56 and a beta of 1.28. The business has a 50 day moving average of $13.30 and a 200-day moving average of $13.92.

Hedge Funds Weigh In On Evolus

Several large investors have recently bought and sold shares of EOLS. KBC Group NV acquired a new position in Evolus in the fourth quarter valued at $49,000. IFP Advisors Inc boosted its stake in shares of Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after buying an additional 4,709 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus during the fourth quarter worth about $106,000. Rafferty Asset Management LLC acquired a new stake in shares of Evolus during the fourth quarter worth about $115,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Evolus during the fourth quarter worth about $118,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, March 5th. Barclays upped their price objective on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Wednesday, March 5th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.